Patents Examined by Jane Fan
  • Patent number: 6780882
    Abstract: There is provided a solid pharmaceutical composition having active ingredients that include at least one non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor, for example, omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, is present in an amount of approximately 5 mg to approximately 300 mg; and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form can be non-enteric coated and can be in the form of a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition of the present invention.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: August 24, 2004
    Assignee: The Curators of the University of Missouri
    Inventor: Jeffrey O. Phillips
  • Patent number: 6716859
    Abstract: The present invention is directed to substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs thereof, represented by the Formulae I and II: wherein Ar1, Ar2, and R1-R2 are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: April 6, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John Drewe, Han-Zhong Zhang
  • Patent number: 6706736
    Abstract: Compounds of the formula useful for the treatment of depression such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: March 16, 2004
    Assignee: Wyeth
    Inventors: Gary P. Stack, Hong Gao, Elizabeth S. Gildersleeve
  • Patent number: 6699885
    Abstract: Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 19, 2002
    Date of Patent: March 2, 2004
    Assignee: The Curators of the University of Missouri
    Inventor: Jeffrey O. Phillips
  • Patent number: 6696470
    Abstract: A compound of the formula: and its pharmaceutically effective salts, wherein R1 and R2 are independently selected from the following: (a) hydrogen, halo, R5—, C2-6 alkenyl, C2-6 alkynyl, hydroxy-R5—, R5—O—R5—, or the like; (b) Ar—, Ar—R5—, Ar—C2-6 alkenyl, Ar—C2-6 alkynyl, Ar—O—, Ar—O—R5— or the like; (c) R5—C(O)—, —NO2, cyano, NH2—C(O)—, R5—NH—C(O)—, (R5)2—N—C(O)—, Ar—C(O)— or the like; and (d) R5—C(O)—NH—, Ar—C(O)—NH— or the like; wherein Ar is optionally substituted aryl or heteroaryl such as phenyl and pyridyl; and wherein R5 is optionally halo-substituted C1-6 alkyl; R3 is selected from the following: (e) cyano, formyl, tetrazolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, R5—C(O)—, C2-6 alkenyl-C(O)—, C2-6 alkynyl-C(O)—, R5—C(O)—R5—, or the
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: February 24, 2004
    Assignee: Pfizer Inc.
    Inventors: Akiyoshi Kawai, Makoto Kawai
  • Patent number: 6693118
    Abstract: The invention relates to the use of a compound of formula (I): for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-&bgr;1.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: February 17, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Françoise Bono-Combie, Jacqueline Fournier, Jean Marc Herbert, Isabelle Lamarche, Umberto Guzzi
  • Patent number: 6689889
    Abstract: The present invention relates to the use of optically active polymers of N-acryloyl-phenylalanine neomenthylamide as such, in crosslinked form and/or in carrier-bonded form as stationary phases for the chromatographic separation of enantiomers of lactones.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: February 10, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Walter Lange, Rolf Grosser, Burkhard Köhler, Stefan Michel, Bruno Bömer, Uwe Zweering
  • Patent number: 6680338
    Abstract: Compounds having therapeutic utility are of formula (I) B—X—(CH2)n—CR2R3—CR4R5—COY  (I) wherein n=0-1; X is S(O)0-2; Y is OR1 or NHOH; R2 and R4 are independently H or a group (optionally substituted with R10) selected from C1-6 alkyl, C2-6 alkenyl, aryl, C1-6 alkyl-aryl, heteroaryl, C1-6 alkyl-heteroaryl, heterocycloalkyl, C1-6 alkyl-heterocycloalkyl, cycloalkyl and C1-6 alkyl-cycloalkyl; and R1, R3 and R5 are independently H or C1-6 alkyl, provided that not more than two of R2, R3, R4 and R5 are H; or any of CR2R3, CR4R5 and CR2—CR4 is a cycloalkyl or heterocycloalkyl ring optionally substituted with R10 or a group (optionally substituted with R10) selected from C1-6 alkyl, aryl, C1-6 alkyl-aryl, heteroaryl and C1-6 alkyl-heteroaryl; B is heterocycloalkyl (optionally substituted by R6 or R7) bonded through carbon to X, or C1-6 alkyl-heterocycloalkyl (optionally substituted with R6 or R7), or a group (substituted with R6) selected from C1-8 alkyl
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: January 20, 2004
    Assignee: Darwin Discovery Ltd.
    Inventors: John Gary Montana, Andrew Douglas Baxter, David Alan Owen, Robert John Watson
  • Patent number: 6677455
    Abstract: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: January 13, 2004
    Assignee: AstraZeneca AB
    Inventors: Anders Kronström, Eva Leander, Anders Mattson
  • Patent number: 6673745
    Abstract: The invention relates to novel compounds of formula I: wherein R, A, B and X have the meaning given in claim 1; and the agronomically acceptable salts or N-oxides thereof, and to herbicidal compositions containing such compounds as active ingredients.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: January 6, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Thomas Maier, Stefan Scheiblich, Helmut S. Baltruschat
  • Patent number: 6673819
    Abstract: The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: January 6, 2004
    Assignee: AstraZeneca AB
    Inventors: Rolf Bergman, Arne Eek, Lars-Inge Olsson, Per Lindberg
  • Patent number: 6670307
    Abstract: 1,3-Oxazoline and 1,3-thiazoline derivatives, their preparation, and their use as pesticides 1,3-Oxazoline and 1,3-thiazoline derivatives of the formula (I) where the symbols have the following meanings: A is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl or thienyl, E is a single bond, (C1-C4)alkylene, —O—CH2— or —CH2—O—; G is a radical selected from the group consisting of Z is oxygen or sulfur. Compounds of the formula (I) have, in particular, a very good acaricidal and insecticidal action with regard to the spectrum of action and the potency.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: December 30, 2003
    Assignee: Hoechst Schering AgrEvo GmbH
    Inventors: Stefan Schnatterer, Manfred Kern, Ulrich Sanft, Christina Mertens
  • Patent number: 6667322
    Abstract: Compounds of the formula useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: December 23, 2003
    Assignee: Wyeth
    Inventors: Jonathan Laird Gross, Richard Eric Mewshaw, Gary Paul Stack
  • Patent number: 6667325
    Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)—(A)n—Y, —CH2—CH(R4)—(A)n—Y, —CO—B1—A—Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group. These substituted pyrazole compounds or their salts have an excellent p38MAP kinase inhibiting effect and are hence useful in the prevention or treatment of tumor necrosis factor &agr;-related diseases, interleukin 1-related diseases, interleukin 6-related diseases or cyclooxygenase II-related diseases.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: December 23, 2003
    Assignee: Teikoku Hormone Mfg. Co., Ltd.
    Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
  • Patent number: 6664276
    Abstract: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: December 16, 2003
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Akira Fujishima, Isao Aoki, Keiji Kamiyama
  • Patent number: 6664277
    Abstract: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: December 16, 2003
    Assignee: PPD Discovery, Inc.
    Inventors: Bradley B. Brown, Kenneth S. Rehder, Jon-Paul Strachan, Jeron H. Eaves, Christopher T. Lowden
  • Patent number: 6656948
    Abstract: Compounds of the following formula: wherein all variables are as defined in the specification. The compounds have cytotoxic properties and can therefore be used in the treatment of malignant tumors.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: December 2, 2003
    Assignee: Universidad Complutense de Madrid
    Inventors: José Luis Fernandez Puentes, Dolores Garcia Gravalos, Carmen Avendano Lopez, Maria del Mar Blanco Castro, Jose Carlos Menendez Ramos
  • Patent number: 6653481
    Abstract: Amlodipine and related analogues thereof are prepared by the following general reaction scheme: R1 and R2 each independently represent a C1-C4 alkyl group. The process provides for the formation of compounds of formula (1) in good yield and purity. Further, the compounds of formula (1) can be used as calcium channel blockers or as reference standards or reference markers for checking the purity of amlodipine.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: November 25, 2003
    Assignee: Synthon BV
    Inventors: Theodorus H. A. Peters, Franciscus B. G. Benneker, Pavel Slanina, Jiri Bartl
  • Patent number: 6649636
    Abstract: This invention relates to a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein A and R1 are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R2 is (C1-C4)alkyl optionally substituted with halo, amino or an alkyl amino; R3 and R4 are each hydrogen, halo, (C1-C4)alkyl optionally substituted with halo and the like; and X1 to X4 are each hydrogen, halo, hydroxy, (C1-C4)alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 18, 2003
    Assignee: Pfizer Inc.
    Inventors: Kazuo Ando, Martha L. Minich, Jin Li, Subas M. Sakya, Kristin M. Lundy, Hengmiao Cheng, Brian S. Bronk, Kiyoshi Kawamura, Tomoki Kato
  • Patent number: RE38624
    Abstract: The invention relates to new hydroxyindoles of the Formula, their use as inhibitors of phosphodiesterase 4 and processes for their preparation.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: October 12, 2004
    Assignee: Elbion AG
    Inventors: Norbert Hofgen, Ute Egerland, Hildegard Kuss, Degenhard Marx, Stefan Szelenyi, Thomas Kronbach, Emmanuel Polymeropoulos, Sabine Heer